AllSci News
Quotient Therapeutics and Merck launch USD 2.2b somatic genomics collaboration for IBD drug targets
Quotient Therapeutics and Merck have entered a multi-year research collaboration to discover novel drug targets in inflammatory bowel disease using...
AstraZeneca's Imfinzi Approved in EU for Early-Stage and Locally Advanced Gastric Cancer
The European Commission has approved Imfinzi (durvalumab) in combination with FLOT chemotherapy as the first perioperative immunotherapy for adults with...
Starget Pharma Closes USD 18 Million Series A to Advance AI-Driven Radioligand Therapy Pipeline
Starget Pharma Inc., a clinical-stage radiopharmaceutical company with operations in the United States and Israel, has closed a USD 18 million Series A...
Oncolytics Biotech's Pelareorep Secures US FDA Fast Track Designation for KRAS-Mutant Colorectal Cancer
Oncolytics Biotech Secures FDA Fast Track for Pelareorep in Hard-to-Treat Colorectal Cancer
Monash University and ClinChoice partner to accelerate early-phase clinical trials across multiple therapeutic areas
Monash University and ClinChoice Enter Clinical Development Partnership Focused on Early-Phase Trials
Lunai Bioworks receives US patent for AI-driven data debiasing methods in drug discovery predictions
Lunai Bioworks, Inc. (NASDAQ: LNAI), an AI-driven biotechnology company headquartered in Sacramento, California, announced on 19 February 2026 that the US...
MHRA Approves CStone's Cejemly for Unresectable Stage III NSCLC Consolidation Therapy in UK
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Cejemly (sugemalimab) as a monotherapy for adult patients with unresectable...
Karyopharm's selinexor doubles spleen response in myelofibrosis but misses symptom endpoint in Phase III
Karyopharm Therapeutics (Nasdaq: KPTI) reported topline results from its Phase III SENTRY trial in myelofibrosis, showing that selinexor combined with...
Angitia Biopharmaceuticals Raises $130M in Series D to Advance Musculoskeletal Disease Therapies
Angitia Biopharmaceuticals Secures USD 130 Million in Series D Financing to Advance Musculoskeletal Therapeutics
Relmada Therapeutics raises USD 160m in oversubscribed private placement financing
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company based in Coral Gables, Florida, announced a private placement financing expected to...
LB Pharmaceuticals raises USD 100m in strategic private placement
LB Pharmaceuticals Secures $100 Million in Strategic Private Placement Financing
Tempest Therapeutics selects Cincinnati Children's AGCTC for TPST-2003 CAR-T manufacturing partnership
Tempest Therapeutics, Inc. (Brisbane, California; Nasdaq: TPST) selected Cincinnati Children's Applied Gene and Cell Therapy Center (AGCTC) (Cincinnati,...
Cancer Grand Challenges Awards USD 125M in Series Grants to Five Global Research Teams
Cancer Grand Challenges Awards USD 125m to Five Global Research Teams
Turn Therapeutics Secures Up to $25 Million in Growth Capital to Advance Dermatology Pipeline
Turn Therapeutics, a clinical-stage dermatology company headquartered in Los Angeles, has secured up to USD 25 million in growth capital financing from...
Sciwind Biosciences' Ecnoglutide Approved in China for Chronic Weight Management in Adults
China's NMPA Approves Ecnoglutide, the First cAMP-Biased GLP-1 Receptor Agonist for Chronic Weight Management
The AllSci Brief
Systematic R&D and deal news. Daily.